OGN - Will Organon Q4 earnings bring positive surprise?

Organon (NYSE:OGN) is scheduled to announce Q4 earnings results on Thursday, February 17th, before market open. The consensus EPS Estimate is $1.27 and the consensus Revenue Estimate is $1.58B. Over the last 3 months, EPS estimates have seen 2 upward revisions and 3 downward. Revenue estimates have seen 1 upward revision and 1 downward. The chart below shows 6-month total return performance of OGN and its peers Jazz, Bausch Health and Teva: The company's stock declined -5.21% on Nov. 11, 2021, the day it reported its Q3 results which beat analysts' estimates. Organon, a Merck spinoff focused on women’s health and biosimilars, had narrowed its full-year guidance. The company revised its guidance for revenue and adjusted EBITDA margin to $6.2B - 6.3B and 36.5%-37.5% from $6.1B-$6.4B and 36%-38% estimated previously, respectively. The company also announced that it was acquiring Forendo Pharma for $954M. On Feb. 16, Organon (NYSE:OGN) said it acquired the rights to oral hormonal

For further details see:

Will Organon Q4 earnings bring positive surprise?